Nxera Pharma Co., Ltd. (TYO:4565)
953.00
-55.00 (-5.46%)
Jun 3, 2026, 3:30 PM JST
Nxera Pharma Employees
Nxera Pharma had 354 employees as of March 31, 2026. The number of employees decreased by 20 or -5.35% compared to the same quarter last year.
Employees
354
Change
-20
Growth
-5.35%
Revenue / Employee
96.69M JPY
Profits / Employee
-28.18M JPY
Market Cap
92.47B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 354 | -20 | -5.35% |
| Dec 31, 2025 | 382 | 8 | 2.14% |
| Sep 30, 2025 | 384 | 12 | 3.23% |
| Jun 30, 2025 | 389 | 29 | 8.06% |
| Dec 31, 2024 | 374 | 24 | 6.86% |
| Sep 30, 2024 | 372 | 24 | 6.90% |
| Jun 30, 2024 | 360 | 149 | 70.62% |
| Mar 31, 2024 | 364 | 157 | 75.85% |
| Dec 31, 2023 | 350 | 148 | 73.27% |
| Sep 30, 2023 | 348 | 149 | 74.87% |
| Jun 30, 2023 | 211 | 6 | 2.93% |
| Mar 31, 2023 | 207 | 10 | 5.08% |
| Dec 31, 2022 | 202 | 4 | 2.02% |
| Sep 30, 2022 | 199 | 3 | 1.53% |
| Jun 30, 2022 | 205 | 17 | 9.04% |
| Mar 31, 2022 | 197 | 4 | 2.07% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Takara Bio | 1,779 |
| GNI Group | 990 |
| PeptiDream | 645 |
| Japan Tissue Engineering | 204 |
| Healios K.K. | 75 |
| Cuorips | 56 |
| AnGes | 56 |
| StemRIM | 45 |
Nxera Pharma News
- 1 day ago - Nxera's Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea - GlobeNewsWire
- 7 days ago - Nxera's President & CEO to Participate in a ‘Fireside Chat' at the Jefferies New York Healthcare Conference 2026 - GlobeNewsWire
- 23 days ago - Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing - GlobeNewsWire
- 25 days ago - Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology - GlobeNewsWire
- 4 weeks ago - Nxera Pharma Quarterly report: Q1 2026 - Filings
- 6 weeks ago - Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases - GlobeNewsWire
- 7 weeks ago - Nxera Pharma's QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia - GlobeNewsWire
- 7 weeks ago - Nxera Pharma's Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia - GlobeNewsWire